1. Predictors of Survival After Operation Among Patients With Large Cell Neuroendocrine Carcinoma of the Lung 
Florian Eichhorn, MD, Hendrik Dienemann, MD, PhD, Thomas Muley, MD, Arne Warth, MD, Hans Hoffmann, MD, PhD 
The Annals of Thoracic Surgery 
Volume 99, Issue 3, Pages (March 2015)
DOI: /j.athoracsur
Copyright © 2015 The Society of Thoracic Surgeons Terms and Conditions

2. Fig 1
Tumor-specific survival was 87%, 65%, and 55% after 1, 2, and 3 years, respectively.
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2015 The Society of Thoracic Surgeons Terms and Conditions

3. Fig 2
(A) Higher stage of disease and (B) advanced nodal status had a significant influence on tumor-specific survival.
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2015 The Society of Thoracic Surgeons Terms and Conditions

4. Fig 3
Immunohistochemical analysis. Overall survival was not significantly influenced by single expression of (A) CD56 (p < 0.29), (B) chromogranin-A (CGA) (p < 0.42), (C) neuronal specific enolase (NSE) (p < 0.46), or (D) synaptophysin (SYN) (p < 0.45).
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2015 The Society of Thoracic Surgeons Terms and Conditions

5. Fig 4
Simultaneous expression of both CD56 and chromogranin-A (CGA) (p = 0.04) or one of each (p < 0.013) was associated with poorer outcome and higher risk of recurrence.
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2015 The Society of Thoracic Surgeons Terms and Conditions